Merck shares advanced 2.1% in pre-open trading following a third-quarter report that exceeded analyst expectations on both profit and revenue. The company posted adjusted earnings per share of $2.49, compared with the roughly $2.09 analysts had forecast. Revenue came in at $18.1 billion, topping the consensus estimate of about $17.3 billion.
Management also updated its full-year outlook, raising the low end of revenue guidance to $66.8 billion and tightening its adjusted earnings per share range to $2.77 to $2.82, up from the prior $2.66 to $2.76 range. Those revisions underscored management's increased confidence in the remainder of the year based on quarterly results.
Product performance was a focal point of the quarter. Sales of Keytruda increased 6% year-over-year to $8.6 billion, above analyst expectations of $8.0 billion. Of that total, $830 million was attributed to the newer, subcutaneously administered formulation, Keytruda QLEX. At the same time, WINREVAIR recorded sales of $694 million, a 93% increase from the year-ago quarter, highlighting a shift toward broader revenue diversification beyond Keytruda.
Institutional reaction included analyst action from major firms. JPMorgan set a new price target of $165 on the stock, while Jefferies maintained its Buy rating and raised its target to $177. Those moves reflect investor and analyst confidence in the company's commercial momentum and pipeline trajectory following the quarterly report.
The stock's pre-market advance unfolded against a cautious macro environment. The Federal Reserve had held its benchmark policy rate at 3.75% to 4.00% in a 10-2 vote the previous evening and described economic activity as expanding at a strong pace while noting that inflation remains elevated. U.S. equity futures suggested a softer, tech-led open, with Nasdaq 100 futures down about 1% and S&P 500 futures off roughly 0.25%. Additionally, GDP and PCE inflation data were scheduled for release the morning of the trading session, contributing to broader market uncertainty.
Why the stock moved
The combination of a clear earnings beat, an upgraded full-year profit outlook, and solid contributions from both an established oncology blockbuster and newer growth products provided a company-specific driver for investors to bid Merck higher. Those results allowed the stock to outperform a generally flat-to-negative pre-market tape.
Longer-term context highlighted by the company
While the quarter provided concrete evidence of commercial traction - from Keytruda QLEX to WINREVAIR and other oncology assets in development - the company acknowledged that questions remain beyond the immediate results. In particular, longer-term concerns about Keytruda's patent expiration in 2028 remain a background issue for investors and industry observers.
Overall, today’s performance reflected both immediate commercial success and ongoing progress in diversifying revenue streams, set against macroeconomic headwinds and scheduled economic data releases that could influence broader market sentiment.